Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On ImmunoCellular Therapeutics, Ltd.


Recently stock market analysts have updated their consensus ratings on shares of ImmunoCellular Therapeutics, Ltd. (IMUC).

Most recent broker ratings

08/23/2016 – ImmunoCellular Therapeutics, Ltd. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 2 price target on the stock.

11/12/2015 – ImmunoCellular Therapeutics, Ltd. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 3 price target on the stock.

05/13/2015 – ImmunoCellular Therapeutics, Ltd. was downgraded to “hold” by analysts at Zacks.

12/12/2013 – ImmunoCellular Therapeutics, Ltd. was downgraded to “hold” by analysts at MLV & Co. They now have a USD 1.25 price target on the stock.

12/12/2013 – ImmunoCellular Therapeutics, Ltd. had its “buy” rating reiterated by analysts at Summer Street.

ImmunoCellular Therapeutics, Ltd. has a 50 day moving average of 0.11 and a 200 day moving average of 0.20. The stock’s market capitalization is 10.62M, it has a 52-week low of 0.08 and a 52-week high of 0.53.

The share price of the company (IMUC) was up +3.49%, with a high of 0.10 during the day and the volume of ImmunoCellular Therapeutics, Ltd. shares traded was 1689019.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.